XOMA Royalty (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average – Time to Sell?

XOMA Royalty Corporation (NASDAQ:XOMA) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $30.68 and traded as high as $41.78. XOMA Royalty shares last traded at $41.54, with a volume of 121,744 shares.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on XOMA shares. Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. Lucid Cap Mkts downgraded shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. TD Cowen upgraded shares of XOMA Royalty to a “hold” rating in a report on Friday, February 13th. HC Wainwright downgraded shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a report on Thursday, April 30th. Finally, Weiss Ratings downgraded shares of XOMA Royalty from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, XOMA Royalty has an average rating of “Hold” and an average price target of $53.75.

XOMA Royalty Trading Down 0.4%

The business’s fifty day moving average is $36.10 and its 200-day moving average is $30.80. The stock has a market capitalization of $524.46 million, a PE ratio of 26.64 and a beta of 0.90. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.96.

XOMA Royalty (NASDAQ:XOMA) last released its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. The company had revenue of $12.32 million during the quarter, compared to analysts’ expectations of $13.91 million. As a group, analysts anticipate that XOMA Royalty Corporation will post 0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP lifted its position in XOMA Royalty by 207.7% during the first quarter. Dimensional Fund Advisors LP now owns 133,360 shares of the biotechnology company’s stock valued at $4,182,000 after buying an additional 90,025 shares in the last quarter. Bank of New York Mellon Corp boosted its position in XOMA Royalty by 9.7% during the 1st quarter. Bank of New York Mellon Corp now owns 74,984 shares of the biotechnology company’s stock worth $2,352,000 after purchasing an additional 6,600 shares during the period. Opaleye Management Inc. boosted its position in XOMA Royalty by 14.7% during the 4th quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after purchasing an additional 37,503 shares during the period. Squarepoint Ops LLC purchased a new stake in XOMA Royalty during the 4th quarter worth $237,000. Finally, Panagora Asset Management Inc. boosted its position in XOMA Royalty by 24.2% during the 4th quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock worth $564,000 after purchasing an additional 4,135 shares during the period. 95.92% of the stock is owned by institutional investors and hedge funds.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.